Anavex announces initiation of ATTENTION-AD ANAVEX 2-73 extension study
Anavex Life Sciences Corp. announced the initiation of the ATTENTION-AD, a long-term extension study for patients with Early Alzheimer's disease and treated with ANAVEX 2-73. The ATTENTION-AD study, which is an extension of the Phase 2b/3 ANAVEX 2-73-AD-004 clinical study currently underway, will give AD patients an opportunity to continue their treatment. This study is expected to last two years for patients included in the ANAVEX 2-73-AD-004 study, once they have completed the placebo-controlled 48-week Phase 2b/3 trial. ATTENTION-AD will be conducted in parallel with the Phase 2b/3 ANAVEX 2-73-AD-004 study. All patients who participate in the Phase 2b/3 ANAVEX 2-73-AD-004 study will be eligible to participate also in the ATTENTION-AD study under a voluntary open label extension protocol.